Media coverage about Proteostasis Therapeutics (NASDAQ:PTI) has been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.1343168900126 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Proteostasis Therapeutics (NASDAQ PTI) traded down $0.03 during midday trading on Thursday, hitting $4.25. The stock had a trading volume of 673,206 shares, compared to its average volume of 749,176. The firm has a market capitalization of $140.73 and a price-to-earnings ratio of -1.92. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. sell-side analysts expect that Proteostasis Therapeutics will post -2.47 EPS for the current fiscal year.

A number of research firms have recently commented on PTI. Leerink Swann raised their price target on Proteostasis Therapeutics from $6.00 to $8.00 in a research report on Tuesday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a research report on Tuesday, December 19th. Robert W. Baird raised their price target on Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Zacks Investment Research lowered Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th. Finally, ValuEngine lowered Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $16.00.

In other news, insider Meenu Chhabra acquired 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average cost of $5.00 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the insider now owns 50,218 shares in the company, valued at $251,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $4.88, for a total value of $2,459,651.76. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 2,100,000 shares of company stock valued at $10,500,000. 17.40% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Proteostasis Therapeutics (PTI) Earns Daily Coverage Optimism Score of 0.08” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with's FREE daily email newsletter.